2022
Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS
Shapiro A, Kushnir V, Seifer D. Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS. 2022, 511-525. DOI: 10.1007/978-3-030-92589-5_25.Peer-Reviewed Original ResearchPolycystic ovary syndromeAnti-Mullerian hormonePathophysiology of PCOSSerum anti-Mullerian hormoneElevated AMH levelsAvailable treatment modalitiesNovel therapeutic approachesFuture therapeutic targetsChronic anovulationOvulatory dysfunctionAMH levelsOvary syndromeOvulatory functionTreatment modalitiesNormal folliculogenesisTherapeutic approachesTherapeutic targetPatientsCritical roleAnovulationDysfunctionPathophysiologySyndromeFolliculogenesisHormoneEmerging Concepts: Role of Vitamin D Deficiency in the Pathogenesis of PCOS
Simpson S, Pal L, Seifer D. Emerging Concepts: Role of Vitamin D Deficiency in the Pathogenesis of PCOS. 2022, 489-509. DOI: 10.1007/978-3-030-92589-5_24.Peer-Reviewed Original ResearchPolycystic ovary syndromeVitamin D deficiencyD deficiencyVitamin DDiabetes mellitusCardiovascular diseaseInsulin resistanceContext of PCOSPathogenesis of PCOSType 2 diabetes mellitusParacrine/autocrine roleSpectrum of morbidityMultiple clinical studiesPoor reproductive outcomesAbnormal reproductive functionFeatures of depressionNonhuman primate studiesFemale reproductive tractImpaired folliculogenesisOvary syndromeEndometrial cancerCommon endocrinopathySkeletal healthClinical associationsLifetime risk
2018
Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility
Butts SF, Seifer DB, Koelper N, Senapati S, Sammel MD, Hoofnagle AN, Kelly A, Krawetz SA, Santoro N, Zhang H, Diamond MP, Legro RS, Network E. Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. The Journal Of Clinical Endocrinology & Metabolism 2018, 104: 369-378. PMID: 30085176, PMCID: PMC6300410, DOI: 10.1210/jc.2018-00750.Peer-Reviewed Original ResearchConceptsVitamin D deficiencyPolycystic ovary syndromeD deficiencyEarly pregnancy lossOvarian stimulationUnexplained infertilityLive birthsPregnancy lossDiagnosis of PCOSMultiple Intrauterine GestationsOvarian stimulation outcomesRetrospective cohort studyInvestigation of womenBanked seraPPCOS IICohort studyIntrauterine gestationOvary syndromeInfertile womenInfertility diagnosisPregnant subjectsElevated riskImportant treatmentReproductive outcomesTrial data
2017
Ovarian reserve testing: a user’s guide
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. American Journal Of Obstetrics And Gynecology 2017, 217: 129-140. PMID: 28235465, DOI: 10.1016/j.ajog.2017.02.027.Peer-Reviewed Original ResearchConceptsOvarian reserve testingOvarian reserve testsOvarian reserveAntimüllerian hormoneDay 3 follicle-stimulating hormonePolycystic ovary syndromeFemale cancer patientsFollicle-stimulating hormoneFertility treatment optionsSelection of treatmentAntral follicular countAge-specific valuesGood predictive valueComplex clinical phenomenonOvarian hyperstimulationOvarian stimulationOvary syndromeGonadotoxic therapyTreatment optionsCancer patientsPoor responseReproductive ageFollicular countReproductive endocrinologistsTreatment protocol
2016
Biosimilar FSH preparations- are they identical twins or just siblings?
Orvieto R, Seifer DB. Biosimilar FSH preparations- are they identical twins or just siblings? Reproductive Biology And Endocrinology 2016, 14: 32. PMID: 27301324, PMCID: PMC4908720, DOI: 10.1186/s12958-016-0167-8.Peer-Reviewed Original ResearchConceptsFSH preparationsPregnancy rateClinical practicePhase 3 clinical trialsIncidence of OHSSOngoing pregnancy ratePolycystic ovary syndromeAdditional patient populationsPopulation of womenDose-response curveRecombinant FSH preparationsBiosimilar productsNormal respondersIVF failurePoor respondersOvary syndromeClinical efficacyPatient populationClinical trialsBiosimilar agentsSteelman-PohleyClinical useFurther comparative studiesPatientsIdentical twins
2015
Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial
Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, Irani S, Tal O, Lambert-Messerlian G, Tal R. Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 4307-4314. PMID: 26485217, DOI: 10.1210/jc.2015-2580.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDBiological AvailabilityCholecalciferolDehydroepiandrosterone SulfateEndoglinFemaleHumansInsulin ResistanceLipidsPolycystic Ovary SyndromeProspective StudiesReceptors, Cell SurfaceSocioeconomic FactorsTestosteroneTransforming Growth Factor beta1Vitamin DVitamin D DeficiencyVitaminsYoung AdultConceptsPolycystic ovary syndromeVD supplementationTGF-β1Clinical manifestationsClinical parametersAcademic-affiliated medical centerFerriman-Gallwey scoreOral vitamin D3Serum TGF-β1Soluble endoglin levelsPlacebo-controlled trialVitamin D supplementationTGF-β1 levelsNew treatment modalitiesD supplementationOral placeboRandomized PlaceboOvary syndromeVD levelsEndoglin levelsInsulin resistanceTreatment modalitiesMenstrual periodLipid profileVitamin D3
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentIs AMH a regulator of follicular atresia?
Seifer DB, Merhi Z. Is AMH a regulator of follicular atresia? Journal Of Assisted Reproduction And Genetics 2014, 31: 1403-1407. PMID: 25193290, PMCID: PMC4389943, DOI: 10.1007/s10815-014-0328-7.Peer-Reviewed Original ResearchConceptsFollicular atresiaNatural ovarian agingPolycystic ovary syndromeOnset of menopausePremature ovarian insufficiencyTreatment of PCOSDifferent patient populationsBasic science studiesTiming of onsetOvary syndromePatient populationOvarian agingOvarian failureHuman ovaryTreatment strategiesAMH productionOvarian insufficiencyIntraovarian regulatorsGrowth factorCellular originCritical growth factorsCancer therapyMenopauseAtresiaAMHVitamin D Normalizes Abnormally Elevated Serum Antimüllerian Hormone Levels Usually Noted in Women With Polycystic Ovary Syndrome
Irani M, Seifer D, Minkoff H, Merhi Z. Vitamin D Normalizes Abnormally Elevated Serum Antimüllerian Hormone Levels Usually Noted in Women With Polycystic Ovary Syndrome. Obstetrics And Gynecology 2014, 123: 189s. DOI: 10.1097/01.aog.0000447216.52829.8e.Peer-Reviewed Original ResearchPolycystic ovary syndromeVitamin D3 supplementationAntimüllerian hormone concentrationsVitamin D deficiencyD3 supplementationAntimüllerian hormoneD deficiencyHormone concentrationsControl groupVitamin D3 therapyHormone serum levelsNon-PCOS womenSerum of womenAntimüllerian hormone levelsWeeks of supplementationOvulatory dysfunctionD3 therapyDeficient womenOvary syndromeSerum levelsVitamin DMetabolic disturbancesHormone levelsVitamin D3Follicular health
2005
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility And Sterility 2005, 83: 130-136. PMID: 15652898, DOI: 10.1016/j.fertnstert.2004.05.098.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeDoses of metforminObese womenOvary syndromeMenstrual frequencyMetformin treatmentHormone changesReproductive hormone changesMonths of treatmentCohort of folliclesUniversity Teaching HospitalOvarian responseOvarian functionTeaching hospitalMAIN OUTCOMEMIS concentrationsProspective treatmentSubstance levelsMetforminMonthsWomenAssessment periodTreatmentSyndromeDoses